Welcome to our dedicated page for Shineco SEC filings (Ticker: SISI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to SEC filings for Shineco, Inc. (SISI), offering a primary source for understanding the company’s disclosed transactions, capital markets activity, and listing status. Shineco’s reports under the Securities Exchange Act of 1934 include current reports on Form 8-K that describe acquisitions, securities offerings, corporate actions, and developments related to its Nasdaq listing.
For investors analyzing Shineco’s business evolution, Form 8-K filings detail key events such as the completion of the acquisition of a 51% equity interest in InfiniClone Limited, a biotechnology company focused on iPSC technology and regenerative medicine, and the agreement to acquire a majority stake in FuWang (HK) International Company Limited, a medical device manufacturer. Amendments to these filings include audited and unaudited financial statements of acquired businesses and pro forma financial information, which help readers assess how these transactions affect Shineco’s consolidated financial profile.
Shineco’s filings also cover unregistered sales of equity securities under Regulation S, including share offerings to non-U.S. investors, and corporate actions like a reverse stock split approved by its board and stockholders. In addition, multiple Form 8-Ks describe communications with The Nasdaq Stock Market LLC regarding non-compliance with the minimum bid price requirement, hearing processes, decisions by a Nasdaq Hearings Panel and the Nasdaq Listing and Hearing Review Council, and the resulting suspension of trading and delisting determination for Shineco’s common stock.
On Stock Titan, Shineco’s SEC filings are updated as they are released through EDGAR, and AI-powered tools can help summarize the contents of lengthy documents, highlight material items, and surface information about acquisitions, capital raises, listing status, and other disclosed events. Users can review these filings to track Shineco’s regulatory history, structural changes, and key corporate decisions as reported to the SEC.
Shineco, Inc. reports that Nasdaq has affirmed a decision to delist its common stock after the company failed to meet the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). A Nasdaq Hearings Panel denied Shineco’s request for continued listing, and the Nasdaq Listing and Hearing Review Council upheld that decision on October 1, 2025. Nasdaq then lifted its prior stay and suspended trading in Shineco’s common stock effective October 7, 2025.
Shineco has pursued several legal and regulatory avenues to prevent suspension and delisting, including a lawsuit in the U.S. District Court for the Southern District of New York and an emergency petition to the U.S. Court of Appeals for the D.C. Circuit. The District Court dismissed the lawsuit for lack of jurisdiction and the D.C. Circuit denied the emergency petition, allowing Nasdaq’s suspension to take effect. The company intends to appeal the Listing Council’s decision to the SEC and is evaluating additional options, but it warns that there is no assurance it will succeed in resuming trading on a national securities exchange or other platform.
Shineco has completed a significant acquisition of 51% equity stake in InfiniClone Limited, a Hong Kong-based company, on June 18, 2025. The transaction structure includes:
- Cash payment of US$19,895,600
- Issuance of 3,450,000 shares of Shineco common stock
The share issuance was conducted under Regulation S, confirming the seller, Dr. Lim Kah Meng, is not a U.S. person or resident. Following the acquisition, InfiniClone becomes a direct subsidiary of Shineco Life Science Group Hong Kong, a Shineco subsidiary.
The company will file required financial statements and pro forma financial information within 71 days of this report. This strategic acquisition represents a significant expansion of Shineco's business operations in Hong Kong, with potential implications for its market presence in Asia.
Shineco, Inc. (Nasdaq: SISI) has received a Nasdaq staff determination letter indicating non-compliance with the minimum bid-price rule and faces imminent trading suspension. The notice, dated 16 June 2025, cites failure to meet the US$1.00 bid-price requirement under Nasdaq Listing Rule 5550(a)(2). Because the company already executed a reverse stock split within the past 12 months, Rule 5810(c)(3)(A)(iv) renders it ineligible for an additional 180-day grace period.
Unless Shineco appeals, Nasdaq will suspend trading on 25 June 2025 and file Form 25-NSE to remove SISI from listing and registration. The company has until 23 June 2025 to request a hearing before Nasdaq’s Hearings Panel. Shineco states it will submit the hearing request; this automatically stays the suspension and any delisting action until the panel reaches a decision or grants additional time.
The company emphasizes that its underlying operations and the ability to trade its shares on other venues are currently unaffected by the letter. However, investors face heightened liquidity and pricing risk should Nasdaq ultimately delist the shares.